Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $2.1 million.

  • Anika Therapeutics' Share-based Compensation fell 3862.7% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 3273.66%. This contributed to the annual value of $13.1 million for FY2024, which is 1386.21% down from last year.
  • As of Q3 2025, Anika Therapeutics' Share-based Compensation stood at $2.1 million, which was down 3862.7% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Share-based Compensation ranged from a high of $4.1 million in Q2 2023 and a low of $2.1 million during Q3 2025
  • For the 5-year period, Anika Therapeutics' Share-based Compensation averaged around $3.2 million, with its median value being $3.4 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 119130.43% in 2021, then tumbled by 4089.12% in 2024.
  • Anika Therapeutics' Share-based Compensation (Quarter) stood at $3.2 million in 2021, then increased by 20.44% to $3.8 million in 2022, then increased by 0.05% to $3.8 million in 2023, then crashed by 40.89% to $2.3 million in 2024, then decreased by 7.63% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.5 million for Q2 2025, and $3.0 million during Q1 2025.